FILSPARI® Seqirus Pty Ltd
Product name
FILSPARI®
Sponsor
Accepted date
Mar-2026
Active ingredients
sparsentan
Summary of proposed indication
FILSPARI (sparsentan) is proposed to treat adults with primary IgA nephropathy who have high levels of protein in their urine.
Application type
A (new medicine)
Publication date
Mar-2026
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.